CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
LY3143753 (Part A) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02342314
NCT02342314Phase 1Completed
CompareCT.gov

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jan 19, 2015·Updated Mar 13, 2019

In Brief

A Phase 1 clinical trial evaluating LY3143753 (Part A), LY3185643 (Part B), and 2 other interventions for Healthy. Completed, enrolled 68 participants across 1 site.

Detailed Summary

The study involves a single dose of LY3143753 or LY3185643, given as an injection into the abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The study is approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to the start of the study. This study involves Part A (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose level.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 19, 2015
Enrollment StartJan 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.5 years ago

Interventions

LY3143753 (Part A)drug

Administered via SC injection

LY3185643 (Part B)drug

Administered via SC injection

Placebo (Part A and Part B)drug

Administered via SC injection

rGlucagon (Part B)drug

Administered via SC injection